Alnylam Pharmaceuticals, (Brazil) Today
| A1LN34 Stock | BRL 71.35 2.01 2.74% |
Performance0 of 100
| Odds Of DistressLess than 22
|
Alnylam Pharmaceuticals, is trading at 71.35 as of the 11th of January 2025, a 2.74% down since the beginning of the trading day. The stock's open price was 73.36. Alnylam Pharmaceuticals, has about a 22 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 12th of December 2024 and ending today, the 11th of January 2025. Click here to learn more.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. ALNYLAM PHARDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. The company has 2.35 B outstanding shares. More on Alnylam Pharmaceuticals,
Moving against Alnylam Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Alnylam Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Alnylam Pharmaceuticals,'s investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Alnylam Pharmaceuticals, or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Alnylam Pharmaceuticals, (A1LN34) is traded on Sao Paulo Exchange in Brazil and employs 1,453 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 117.12 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alnylam Pharmaceuticals,'s market, we take the total number of its shares issued and multiply it by Alnylam Pharmaceuticals,'s current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Alnylam Pharmaceuticals, operates under Healthcare sector and is part of Biotechnology industry. The entity has 2.35 B outstanding shares.
Alnylam Pharmaceuticals, has accumulated about 1.9 B in cash with (590.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.99.
Check Alnylam Pharmaceuticals, Probability Of Bankruptcy
Alnylam Pharmaceuticals, Risk Profiles
Although Alnylam Pharmaceuticals,'s alpha and beta are two of the key measurements used to evaluate Alnylam Pharmaceuticals,'s performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.76 | |||
| Standard Deviation | 2.71 | |||
| Variance | 7.33 | |||
| Risk Adjusted Performance | 0.0045 |
Alnylam Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Alnylam Pharmaceuticals, without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Breakdown Now
Idea BreakdownAnalyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
| All Next | Launch Module |
Other Information on Investing in Alnylam Stock
Alnylam Pharmaceuticals, financial ratios help investors to determine whether Alnylam Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alnylam with respect to the benefits of owning Alnylam Pharmaceuticals, security.